Health

Brain plasticity promotes worsening of epileptic seizures, study finds | News Center

The researchers focused on a common type called absence seizures, in which all behavior stops, usually for less than a minute. People having such seizures look like they are staring or daydreaming. They also experience brief loss of consciousness; afterward, they don’t know what happened. These seizures, though less dramatic than those that cause convulsions or collapse, still interfere with the lives of epileptic patients and can be dangerous if, for instance, someone has an absence seizure while crossing a street.

Children and adults with certain types of epilepsy can experience hundreds of absence seizures daily. Although medication can treat it, about 30% of patients with childhood absence epilepsy still have seizures even though they’re taking medication.

“For most forms of epilepsy, we don’t have disease-modifying treatment,” Knowles said. “We can give medications that temporarily stop seizures, but this does not address what’s happening structurally in the brain.”

To understand how seizures change the brain, the researchers studied rodents with absence seizures. As in some types of human epilepsy involving absence seizures, the animals develop seizures in early life that gradually ramp up over time.

In the brains of rats with absence epilepsy, the researchers looked at changes to myelin-forming cells called oligodendrocytes. Compared with the time before seizures began, by the end of the period of seizure onset — 4.5 months later — the animals had more and a greater density of new or dividing oligodendrocyte precursor cells, and more mature oligodendrocytes.

This finding corresponded with the presence of thicker myelin coating on the nerve fibers — and more nerve fibers with myelin — in the brain region where seizures occur. However, there was no change in myelination in brain regions where seizures are uncommon. In addition, control animals without seizures did not show these changes.

To find out if interrupting the seizure-induced myelination could block the development of seizures, the researchers genetically engineered mice to further their understanding of absence epilepsy. The scientists changed an important receptor in mice oligodendrocyte precursor cells that is needed for adaptive myelination. Because of the genetic engineering, the researchers could selectively delete the receptor, TrkB, from the oligodendrocyte precursor cells in these mice beginning when the seizures were expected to start. When TrkB was deleted, the mice still had some seizures, but the number of seizures was lower, and they did not become more frequent.

The researchers also used a drug that blocks aspects of the maturation of oligodendrocyte precursor cells, administering the drug starting one week after the mice began having seizures. The findings were similar to those in genetically engineered mice: Seizures still occurred, but they did not become worse or more frequent.

The class of drugs used in the study, HDAC inhibitors, includes some FDA-approved medications. The scientists hope to study whether such drugs could improve outcomes, particularly in children newly diagnosed with severe forms of epilepsy.

“There’s a lot more that needs to be done to explore the molecular mechanisms that link pathological patterns of neuronal activity to maladaptive myelination and explore the potential of HDAC inhibition for severe and refractory epilepsy,” Knowles said.

The study’s other Stanford authors are life science researchers Haojun Xu, Ankita Batra, Lijun Ni and Sydney Talmi; undergraduate student Tristan Saucedo; medical student Lydia Tam; and former research assistants Caroline Soane, Eleanor Frost, Danielle Fraga and Katlin Villar.

The authors include members of Stanford Bio-Xthe Stanford Maternal and Child Health Research Institutethe Stanford Wu Tsai Neurosciences Institutethe Stanford Institute for Stem Cell Biology and Regenerative Medicineand the Stanford Cancer Institute.

The research was funded by the National Institute of Neurological Disorders and Stroke (grants R01NS092597, K12NS098482, K08NS119800, R01NS034774 and R01NS117150), an NIH director’s pioneer award (grant DP1NS111132), the Robert J. and Helen C. Kleberg Foundation, the Stanford Maternal and Child Health Research Institute, Stanford Bio-X, Cancer Research UK, the American Epilepsy Society, the CURE Epilepsy Foundation, and the Child Neurology Foundation.

Monje is on the scientific advisory board of Cygnal Therapeutics. The authors have no other competing interests.

.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button